Luxa Biotechnology

What Luxa Biotechnology does

Luxa Biotechnology, LLC is a clinical-stage biotechnology company developing a single first-in-class cell therapy, RPESC-RPE-4W, for dry age-related macular degeneration (AMD) and geographic atrophy (GA). The product consists of allogeneic adult retinal pigment epithelial stem cell-derived RPE progenitor cells (at a four-week differentiation stage) that are transplanted under the retina via subretinal injection to replace deteriorated RPE cells. The underlying RPESC technology was developed at and is licensed inbound from the Neural Stem Cell Institute (NSCI) in Rensselaer, New York; the company itself was formed as a joint venture between NSCI and Korea-based Y2 Solution Co. Ltd, and is headquartered in Fort Lee, New Jersey. GMP manufacturing and cryo-preservation are performed at the Cedars-Sinai Biomanufacturing Center in Los Angeles.

The company is running a single first-in-human Phase 1/2a trial (NCT04627428) across three U.S. sites — University of Michigan Kellogg Eye Center (initiated 2022), Retina-Vitreous Associates Medical Group (March 2025), and Stanford University Byers Eye Institute (April 2025). Cohort 1 results reported in Cell Stem Cell (September 2025) covered six patients receiving 50,000 cells with no therapy-related serious adverse events and an average +21.67 ETDRS letter improvement in severely vision-impaired patients sustained through 12 months. The FDA granted RMAT designation in February 2025. The product platform also incorporates a patented TREX long non-coding RNA biomarker used to optimize engraftment and in vivo efficacy.

Luxa is pre-revenue. Its economics are wholly contingent on (a) the company completing later-stage clinical trials, (b) obtaining BLA approval, and (c) successfully commercializing via specialty ophthalmology and retinal treatment centers or licensing agreements. Operating capital to date is predominantly non-dilutive grant funding — approximately $4M from CIRM (May 2024) and an $11M NYSTEM translational grant (Jeffrey Stern, PI) — supplemented by the founders' equity and the Y2 Solution joint venture. Go-to-market is concentrated through Phase 1/2a clinical trial enrollment today, with eventual commercial sales expected to target ophthalmologists and retinal specialists at major eye treatment centers serving dry AMD patients aged 55 and older.

Name

Luxa Biotechnology

Legal name

Luxa Biotechnology, LLC

Website

https://luxabiotech.com

Company type

Private

Founded year

2022

Operating status

Operating

Headcount range

11–50 employees

Short description

Luxa Biotechnology is a clinical-stage biotech developing RPESC-RPE-4W, a first-in-class adult retinal pigment epithelial stem cell therapy transplanted via subretinal injection to restore vision in patients with dry age-related macular degeneration and geographic atrophy, currently in a Phase 1/2a trial with FDA RMAT designation.

Ownership category

akta.pro rank

Product category

Ophthalmic Cell Therapy

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)

SIC

Biological Products, (No Disgnostic Substances) (2836), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Ophthalmic Regeneration (cornea/retina) (HLAAAGAK)

akta.pro secondary industry

Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods) (HLAAABAL)

Keywords

• Regenerative medicine
• RPE cell therapy
• Dry AMD treatment
• Retinal cell replacement
• Ophthalmology biotechnology

Headquarters

HQ city

Fort Lee

HQ country

United States

HQ region

North America

Offices6 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Supply Chain, Infrastructure, Marketing or Sales

Revenue model

1. RPESC-RPE-4W Cell Therapy: Pre-revenue clinical-stage biotechnology company. Future revenue expected from commercialization of RPESC-RPE-4W therapy for dry AMD upon successful clinical trials and FDA approval. Revenue model will likely involve direct sales through specialty ophthalmology centers or licensing agreements.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels7 records

Core offering

Luxa Biotechnology is developing RPESC-RPE-4W, a proprietary adult retinal pigment epithelial stem cell (RPESC)-derived cell therapy for dry age-related macular degeneration (dry AMD) and Geographic Atrophy. The therapy involves the subretinal transplantation of RPESC-RPE-4W cells (a progenitor-stage cell product) under the retina to replace deteriorated retinal pigment epithelial cells and restore vision. The company is currently advancing the product in a Phase 1/2a clinical trial and holds FDA RMAT designation.

Product overview

Luxa Biotechnology is a clinical-stage biotechnology company developing a single proprietary cell therapy product: RPESC-RPE-4W. This adult retinal pigment epithelial stem cell-derived therapy is designed to replace deteriorated RPE cells in patients with dry AMD and Geographic Atrophy. The company is currently conducting a Phase 1/2a first-in-human clinical trial (NCT04627428) to evaluate safety and efficacy. The product has received FDA Regenerative Medicine Advanced Therapy (RMAT) designation.

Differentiator

Problem solved

Functional benefit

Products and services

• RPESC-RPE-4W A proprietary adult retinal pigment epithelial stem cell (RPESC)-derived RPE progenitor-stage cell therapy administered as a subretinal transplant (50,000 cells at the low dose) in the operating room under anesthesia to replace deteriorated retinal pigment epithelial cells and restore or preserve vision in patients with dry age-related macular degeneration (dry AMD) and Geographic Atrophy. Currently in a Phase 1/2a first-in-human trial (NCT04627428) and holding FDA Regenerative Medicine Advanced Therapy (RMAT) designation.

Quantifiable outcome

• Patients with severe vision loss gained average +21.67 ETDRS letters at 12 months - largest vision improvement reported in RPE cell therapy trials for dry AMD
• +3 more outcomes

Named customers1 record

Segments3 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Eight partnerships are on record, tiered major and core.

• Stanford University Byers Eye InstitutemajorStrategic or Co-development Partner · 1 April 2025Clinical trial site initiated April 2025 for Phase 1/2a trial of RPESC-RPE-4W.
• Retina-Vitreous Associates Medical Group (La Retina)majorStrategic or Co-development Partner · 1 March 2025Clinical trial site initiated March 2025 for Phase 1/2a trial of RPESC-RPE-4W.
• University of Michigan Kellogg Eye CentercoreStrategic or Co-development Partner · 1 January 2022FDA Phase I/IIa clinical trial initiated in 2022 at Kellogg Eye Center, Michigan, USA - first clinical trial site.
• Neural Stem Cell Institute (NSCI)coreStrategic or Co-development PartnerNSCI developed the proprietary RPESC technology and licensed it to Luxa. Luxa maintains a robust research program at NSCI to develop the RPESC as an effective, commercially viable cell product. Co-founded by Sally Temple who serves as CSO at Luxa.
• Y2 Solution Co. LtdcoreStrategic or Co-development PartnerJoint venture partner from Seoul, Korea that co-founded Luxa Biotechnology LLC. Part of the founding partnership with Neural Stem Cell Institute.
• Cedars Sinai Biomanufacturing CentercoreStrategic or Co-development PartnerGMP manufacturing and cryo-preservation of RPESC-RPE-4W cells established at Cedars Sinai facility in Los Angeles, USA.
• EmmesmajorStrategic or Co-development PartnerClinical research organization providing support for the Phase 1/2a clinical trial.
• National Eye Institute (NEI)majorStrategic or Co-development PartnerDr. Sally Temple presented at NEI annual meeting on tissue-derived and pluripotent stem cell-derived cells for retinal repair. NEI strategic plan focuses on stem cell technology as priority research area.

Scale indicators8 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• Lineage Cell Therapeutics: Develops OpRegen, an allogeneic RPE cell therapy for dry AMD/GA — the closest direct competitor to Luxa's RPESC-RPE-4W, using a different RPE cell source and subretinal delivery approach.
• Belite Bio: Clinical-stage biotech developing LBS-008 (tinlarebant) for Stargardt disease and dry AMD — a small-molecule RPE-protective approach competing for the same vision-loss patient population.

Broad incumbents

• Apellis Pharmaceuticals: Markets Syfovre (pegcetacoplan), the first FDA-approved therapy for geographic atrophy secondary to dry AMD. Sets the current standard of care against which Luxa's vision-restorative approach will compete.
• Iveric Bio (Astellas): Developed Izervay (avacincaptad pegol) for GA, now commercialized by Astellas following its $5.9B acquisition. Represents the second approved GA therapy and a major strategic benchmark in dry AMD.
• Spark Therapeutics (Roche): Pioneer in ocular gene therapy with Luxturna (RPE65). Acquired by Roche for $4.8B; provides a strategic comp and acquisition precedent for ophthalmology cell/gene therapy platforms like Luxa's.
• Genentech (Roche): Global ophthalmology leader with Lucentis, Vabysmo, and Susvimo for wet AMD, plus a dry AMD pipeline. Sets the bar for ophthalmology commercial infrastructure that Luxa would need to replicate or partner into.

Emerging players

• REGENXBIO: Develops ABVVEGF-Lite and other AAV gene therapies for retinal disease. Competes for the same ophthalmology biologics capital and physician mindshare, though with a gene therapy modality rather than cell therapy.
• jCyte: Develops jCell, an intravitreal allogeneic cell therapy for retinal degenerative diseases including retinitis pigmentosa. Adjacent cell therapy modality targeting the same ophthalmology specialist channel.
• NGM Biopharmaceuticals: Clinical-stage biotech with a dry AMD pipeline (originally licensed to Merck). Competes for the same wet/dry AMD R&D capital and strategic partnership interest.
• Kodiak Sciences: Develops novel biologics for retinal diseases including wet AMD (tarcocimab tedromer). Targets the same retinal specialist prescriber base as a future Luxa commercial launch.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/luxabiotechnology

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Luxa Biotechnology